ALLO
Allogene Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$1.18Close
$270.7MMarket cap
$1.05 – $3.0652-week range
Nov 5, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 8 · weaker than 92% of stocks over 12 months
- Far from its high 61% below its 52-week high
- Distribution down-day volume 2.2× up-day volume over 50 sessions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
61%
1wk
down 5.6%
price change
1mo
down 26.3%
price change
12-month return
down 2%
market up 11% ·
its own down 14%
F-score
—
— Not assessed
Altman Z
-6.46
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
0.9×
price / book
Earnings yield
down 95.6%
EBIT / enterprise value
Cheaper than
32%
of the market · expensive
Revenue growth
down 100%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 53%
return on equity
Free cash margin
—
-$149.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.7%
$0.09 a day · 2×ATR $1.00
RS
8 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.6×
vs 50-day average
Up/down volume
0.46
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 8.1% over the year, from 212m to 229m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 100.0% over the year.
Last reported
Aug 12, 2026
Results reaction
Aug 12, 2026-8% vs market2 sessions after results
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $114.1M | $156,000 | $95,000 | $22,000 | $0 |
| Operating income | -$258.2M | -$180.2M | -$335.5M | -$327.7M | -$273.2M | -$209.3M |
| Net income | -$316.4M | -$182.1M | -$340.4M | -$327.3M | -$257.6M | -$190.9M |
| Net margin | — | -160% | -218214% | -344489% | -1170864% | — |
| Earnings per share | -$2.63 | -$1.34 | -$2.38 | -$2.09 | -$1.32 | -$0.87 |
| Free cash flow | -$181.1M | -$206.3M | -$225.7M | -$239.2M | -$201.0M | -$149.6M |
| Free cash margin | — | -181% | -144686% | -251841% | -913609% | — |
| Cash | $183.4M | $173.3M | $61.9M | $83.2M | $75.2M | $51.7M |
| Shareholders' equity | $1.0B | $925.2M | $666.9M | $512.2M | $422.2M | $292.5M |
| Shares outstanding | 140.47m | 142.62m | 144.44m | 168.64m | 212.21m | 229.41m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 12, 2026 | Quarterly ↗ | Jun 30, 2026 | 43d |
| May 13, 2026 | Quarterly ↗ | Mar 31, 2026 | 43d |
| Mar 12, 2026 | Annual ↗ | Dec 31, 2025 | 71d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 13, 2025 | Annual ↗ | Dec 31, 2024 | 72d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 14, 2024 | Annual ↗ | Dec 31, 2023 | 74d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 2, 2026 | Director or officer change ↗ |
| Aug 12, 2026 | Results ↗ |
| Jun 22, 2026 | Shareholder vote · Other events ↗ |
| May 28, 2026 | Director or officer change ↗ |
| May 13, 2026 | Material agreement · Agreement ended · Results ↗ |
| Apr 15, 2026 | Other events ↗ |
| Apr 13, 2026 | Other events ↗ |
| Apr 13, 2026 | Other events ↗ |
| Mar 12, 2026 | Results ↗ |
| Nov 6, 2025 | Results ↗ |
| Oct 14, 2025 | Other events ↗ |
| Aug 13, 2025 | Results ↗ |